185 Infos zu Heinz Lubenau

61 Aktuelle Nachrichten

VAXIMM GmbH, Die VAXIMM AG, ein schweizerisch/deutsches Biotechnologieunternehmen, das auf die Entwicklung oraler T-Zell-Immuntherapi…

Dr. Heinz Lubenau Oktober 23, Über uns. Kontaktieren Sie uns: . Folgen Sie uns. MEDIADATEN GOING PUBLIC MAGAZIN ...

Heinz Lubenau wird eine Unternehmenspräsentation geben. Details zur Präsentation werden nach Bekanntgabe auf der Webseite von VAXIMM veröffentlicht.

“We are very encouraged by these data,” added Dr. Heinz Lubenau, General Manager of VAXIMM GmbH, a fully owned subsidiary of VAXIMM AG in Germany. “It provides a strong basis for continuing the development of VXM01 for the treatment of solid tumor diseases. Following regulatory approval, we ...

7 Profile in Sozialen Netzwerken

Sehen Sie sich das Karriere-Profil von Heinz Lubenau (Deutschland) auf LinkedIn an. LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und ...

Heinz Lubenaus berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Heinz Lubenau dabei hilft, ...

Heinz Lubenau hat 9 Jobs im Profil angegeben. Sehen Sie sich auf LinkedIn das vollständige Profil an und erfahren Sie mehr über die Kontakte von Heinz Lubenau und über Jobs bei ähnlichen Unternehmen VAXIMM. Früher. VAXIMM,; BioGeneriX AG,; Servier Forschung und Pharmaentwicklung GmbH. Ausbildung. Ontbrekend: sap

Life Sciences Business Intelligence Web Portal for European countries

4 Hobbys & Interessen

— Dr. Heinz Lubenau, Chief Operating Officer und Mitbegründer von VAXIMM, sagte: „Wir freuen uns, diese Allianz mit NEC einzugehen und die ... › news › home

Recent bibliographic sampling of Heinz Lubenau patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title):

— Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM) All actual figures have been sourced and analyzed from publicly available ... › neo...

1 Firmen-Beteiligungen

Vaximm AG in Basel ✓ aktiv ✓ Gegründet ✓ Management: Prof. Dr. Dr. Tomas Dezsö Szucs u.a ✓ Letzte Änderung: ✓

3 Business-Profile

Dr. / Chief Operating Officer / Mannheim / diabetes, Drug development and project management expertise, transition to clinical first-in-human trials, cardiology, national and European Scientific Advice experience, and hypertension., biosimilar development background

BIOGENERIX AG, Neustadt, DE

Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ... Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ...

2 Firmen-Mitarbeiter

Management Team VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise. Supervisory

Dr. Heinz Lubenau hat VAXIMM im Jahr mitgegründet Im Jahr begann er bei Servier und übernahm die Funktion des Clinical Research Manager und ... › ueber-uns

2 Persönliche Webseiten

... Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting.

VAXIMM AG Technologiepark Basel . CH Basel Schweiz. Verwaltungsratspräsident: Dr. Thomas Hecht. VAXIMM GmbH. MAFINEX-Technologiezentrum Mannheim Deutschland. Geschäftsführer: Dr. Heinz Lubenau. . HRB

2 Besitz

This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections....

... Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic ...

2 Bücher zum Namen

von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ... von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ...

... Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M. Breiner, Gerd Mikus ...

5 Dokumente

von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar. von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar.

... Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany ...

... Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip ...

8 Wissenschaftliche Publikationen

Filed: Oct 17, Publication Date: Mar 8, Inventors: Marco SPRINGER (Wendlingen), Heinz LUBENAU (Neustadt an der Weinstrasse)

von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ... von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ...

von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ... von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ...

Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ... Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ...

6 Allgemeine Veröffentlichungen

von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany

Questionaire for VAXIMM: Interview with Dr. Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager. MedLine Citation:.

— Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September — Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September

... contains supplementary material, which is available to authorized users. Andreas G Niethammer, Heinz Lubenau contributed equally to this work.

4 Meinungen & Artikel

22 VAXIMM AG HEINZ LUBENAU COO Heinz Lubenau co-founded VAXIMM in and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to thishe was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, ...

— Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital — Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital ...

— Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the — Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the ...

73 Webfunde aus dem Netz

View Heinz Lubenau's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Heinz Lubenau discover ...

Heinz Lubenau, our CEO and co-founder, will give a company ... Heinz Lubenau, our CEO, will give a company presentation and be part of the ... Heinz Lubenau, our CEO and co-founder, will give a company ... Heinz Lubenau, our CEO, will give a company presentation and be part of the ...

... Inventor: Heinz Lubenau: Holger Siede: Renate Janssen: Marco Springer; Current Assignee (The listed assignees may be inaccurate. › patent

"We have seen encouraging data in several preclinical colorectal cancer models," said Dr. Heinz Lubenau, VAXIMM's Chief Operating Officer and General Manager of VAXIMM GmbH. "The results from this new clinical trial will be important in adding to our knowledge base and guiding the development of ...

Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ... Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ...

— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...

› ...

Dr. Heinz Lubenau, COO und Geschäftsführer der VAXIMM GmbH, kommentierte: "Wir haben in verschiedenen präklinischen ...

Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ... Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ...

Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority. Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority.

› tag

Vaxxim, a Merck business, begins clinical studies for a new oral cancer vaccine. The drug is the first of its kind, the company states, targeting not the tumor...

Nouscom Srl. Heinrich Haas. Vice President Formulation and Drug Development. BioNTech AG. Heinz Lubenau. Chief Executive Officer & Co-Founder. Vaximm GmbH ... › 2...

... Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of ...

Dr. Heinz Lubenau, CEO, Vaximm AG, Germany, Dr. Thomas Justel, Professor, FH Munster University of Applied Sciences, Germany, Dr. Yves Rozenholc, ... › gscf...

Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ... Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ...

... Friedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M Breiner, Gerd Mikus, ...

VAXIMM GmbH, VAXIMM AG, a Swiss-German biotech firm and Merck KGaA spin-off, announced today the start of the first clinical trial of…

von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ... von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ...

von H Lubenau · · Zitiert von: 73 — Dr Heinz Lubenau and Anne-Katrin Maly are employees of BioGeneriX AG, Mannheim, Germany. Dr Peter Bias is an employee of Merckle GmbH, Ulm, Germany, ... › i.do